<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03470155</url>
  </required_header>
  <id_info>
    <org_study_id>REFORM-MR</org_study_id>
    <nct_id>NCT03470155</nct_id>
  </id_info>
  <brief_title>Operative Mitral Valve Reconstruction in Functional mv Insufficiency With Reduced Systolic Ventricle Function</brief_title>
  <acronym>REFORM-MR</acronym>
  <official_title>Operative Mitralklappenrekonstruktion Bei Funktionellen Mitralklappenvitien Bei Reduzierter Systolischer Ventrikelfunktion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional mitral insufficiency poses a challenge with regard to the optimal time of
      intervention, particularly because they are frequently associated with left ventricular (LV)
      dilation and reduced LV ejection fraction (EF). The registry will document the underlying
      pathology by using transthoracal echo cardiography (TTE) with analysis of common tenting
      parameters. OP strategies, data and outcomes will be documented, as well as follow-up data
      for echocardiography, quality of life and MACCE outcomes after 6 months, 1 and 2 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective enrolment of all patients with mitral valve insufficiency and restricted movement
      of leaflets during systole into a multicentric registry. Exact analysis of the underlying
      pathology using TTE with analysis of tenting parameters. In patients without
      contraindications, functional preoperative MRT to determine the functional reserve of
      ventricular function. Documentation of the quality of life of the patients using the SF12
      questionnaire before and after intervention. Documentation of follow-up data (SF12, TTE,
      NT-pro BNP) at 6 months, 1 and 2 years. Development of operative strategies to improve
      long-term outcomes in patients with severe LV dilation (typically accompanied by function
      mitral insufficiency type IIIb).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 3, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>recurrent mitral valve insufficiency &gt; grade 2</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>major adverse cardiovascular and cerebrovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-intervention at mitral valve</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>device therapy (e. g. left ventricular auxiliary device or heart transplant) due to progressive heart failure</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular mortality</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-hospitalisation due to heart failure</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Left Ventricular Systolic Dysfunction</condition>
  <condition>Mitral Valve Prolapse</condition>
  <arm_group>
    <arm_group_label>functional mitral insufficiency op</arm_group_label>
    <description>Patients with functional mitral insufficiency with restricted leaflet movement during systole (type IIIb Carpentier) undergoing operative reconstruction (mitral valve repair)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>mitral valve repair</intervention_name>
    <description>operative reconstruction</description>
    <arm_group_label>functional mitral insufficiency op</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients presenting at participating hospitals with mitral valve dysfunction type III b who
        give written consent to participate in the registry
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  functional mitral valve insufficiency with reduced mobility of leaflets during systole
             (type IIIb) - effective regurgitation orifice area &gt; 20 mm2 / regurgitant volume &gt; 30
             ml/beat

          -  left ventricular ejection fraction &lt;= 50% and /or left ventricular end-diastolic
             diameter &gt;= 60 mm

          -  tenting of the proximal and / or anterior mitral leaflets

        Exclusion Criteria:

          -  prolaps of leaflets (type II mitral regurgitation)

          -  combination intervention with aortic valve repair or replacement

          -  re-operation at mitral valve
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evaldas Girdauskas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäres Herzzentrum Hamburg am UKE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christiane Pohlmann, PhD</last_name>
    <phone>+49(0)4471 85033</phone>
    <phone_ext>28</phone_ext>
    <email>christiane.pohlmann@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerstin Plate</last_name>
    <phone>+49(0)447185033</phone>
    <phone_ext>31</phone_ext>
    <email>kerstin.plate@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herz- u. Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>NRW</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heike Windhagen</last_name>
      <email>hwindhagen@hdz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>Gummert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Kathrin Funkat, PhD</last_name>
      <email>Anne-Kathrin.Funkat@leipzig-heart.de</email>
    </contact>
    <investigator>
      <last_name>Borger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Klinik für kardiovaskuläre Chirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Volkmar Falk, MD</last_name>
      <email>volkmar.falk@charite.de</email>
    </contact>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karel van Praet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörg Kempfert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Herz- und Gefäßchirurgie am UHZ am UKE</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evaldas Girdauskas, MD</last_name>
      <email>egirdauskas@web.de</email>
    </contact>
    <investigator>
      <last_name>Evaldas Girdauskas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Harmel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonas Pausch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>annuloplasty mitral valve</keyword>
  <keyword>reduced LV function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Mitral Valve Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no IPD will be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

